HRP20000380B1 - Oral pharmaceutical extended release dosage form - Google Patents

Oral pharmaceutical extended release dosage form

Info

Publication number
HRP20000380B1
HRP20000380B1 HR20000380A HRP20000380A HRP20000380B1 HR P20000380 B1 HRP20000380 B1 HR P20000380B1 HR 20000380 A HR20000380 A HR 20000380A HR P20000380 A HRP20000380 A HR P20000380A HR P20000380 B1 HRP20000380 B1 HR P20000380B1
Authority
HR
Croatia
Prior art keywords
hydrogen
alkyl
halogen
different
same
Prior art date
Application number
HR20000380A
Other languages
English (en)
Croatian (hr)
Inventor
Karehill Per-Gunnar
Johan Lundberg Per
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20000380A2 publication Critical patent/HRP20000380A2/hr
Publication of HRP20000380B1 publication Critical patent/HRP20000380B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20000380A 1997-12-22 2000-06-08 Oral pharmaceutical extended release dosage form HRP20000380B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II
PCT/SE1998/002368 WO1999032091A1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form

Publications (2)

Publication Number Publication Date
HRP20000380A2 HRP20000380A2 (en) 2001-06-30
HRP20000380B1 true HRP20000380B1 (en) 2007-08-31

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000380A HRP20000380B1 (en) 1997-12-22 2000-06-08 Oral pharmaceutical extended release dosage form

Country Status (39)

Country Link
US (1) US6605303B1 (xx)
EP (1) EP1043976B1 (xx)
JP (1) JP4865945B2 (xx)
KR (2) KR100755154B1 (xx)
CN (1) CN1171582C (xx)
AR (1) AR017201A1 (xx)
AT (1) ATE312602T1 (xx)
AU (1) AU759634B2 (xx)
BG (1) BG65028B1 (xx)
BR (1) BR9814378A (xx)
CA (1) CA2315261C (xx)
CY (1) CY1106072T1 (xx)
CZ (1) CZ299228B6 (xx)
DE (1) DE69832816T2 (xx)
DK (1) DK1043976T3 (xx)
DZ (1) DZ2685A1 (xx)
EE (1) EE04901B1 (xx)
ES (1) ES2252875T3 (xx)
HK (1) HK1034455A1 (xx)
HR (1) HRP20000380B1 (xx)
HU (1) HUP0101437A3 (xx)
IL (2) IL136827A0 (xx)
IS (1) IS5524A (xx)
MA (1) MA26576A1 (xx)
MY (1) MY126555A (xx)
NO (1) NO20003218L (xx)
NZ (1) NZ505127A (xx)
PL (1) PL193776B1 (xx)
RU (1) RU2214232C2 (xx)
SA (1) SA99191077B1 (xx)
SE (1) SE9704869D0 (xx)
SK (1) SK284988B6 (xx)
TN (1) TNSN98229A1 (xx)
TR (1) TR200001981T2 (xx)
TW (1) TWI249410B (xx)
UA (1) UA69397C2 (xx)
WO (1) WO1999032091A1 (xx)
YU (1) YU36700A (xx)
ZA (1) ZA9811239B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL186605B1 (pl) * 1995-09-21 2004-01-30 Pharma Pass Llc Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
HUP0100043A2 (hu) 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
JP2004514737A (ja) * 2000-12-07 2004-05-20 アルタナ　ファルマ　アクチエンゲゼルシャフト 酸分解性活性成分を含有する迅速に崩壊する錠剤
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
CN1681534A (zh) * 2002-09-26 2005-10-12 山之内制药株式会社 药物吸收性改善剂
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1552833B1 (en) 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
AU2005264864B2 (en) * 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
WO2006082523A2 (en) * 2005-01-25 2006-08-10 Aurobindo Pharma Limited Pharmaceutical sustained release composition of metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
JPWO2007074909A1 (ja) * 2005-12-28 2009-06-04 武田薬品工業株式会社 放出制御固形製剤
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US8679541B2 (en) * 2007-03-14 2014-03-25 Particle Dynamics International, Llc Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
CN104069088A (zh) * 2007-10-12 2014-10-01 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
EP2405898A2 (en) 2009-03-09 2012-01-18 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
CN105163743A (zh) 2013-02-13 2015-12-16 红山生物医药有限公司 用于治疗幽门螺杆菌的药物组合物
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (xx) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
AU682827B2 (en) * 1992-09-18 1997-10-23 Astellas Pharma Inc. Sustained-release hydrogel preparation
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
EE03378B1 (et) * 1994-07-08 2001-04-16 Astra Aktiebolag Omeprasooli magneesiumisoola sisaldav peroraalne ravimvorm
ES2100142T3 (es) * 1994-07-08 2002-03-01 Astrazeneca Ab Forma de dosificacion en tabletas i constituida por unidades multiples.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
EE200000383A (et) 2001-12-17
YU36700A (sh) 2003-01-31
KR20060097069A (ko) 2006-09-13
CY1106072T1 (el) 2011-06-08
HRP20000380A2 (en) 2001-06-30
EP1043976A1 (en) 2000-10-18
IL136827A (en) 2007-05-15
DE69832816T2 (de) 2006-08-31
HUP0101437A2 (hu) 2001-10-28
CZ20002314A3 (cs) 2000-11-15
UA69397C2 (uk) 2004-09-15
IS5524A (is) 2000-06-08
AR017201A1 (es) 2001-08-22
CN1284866A (zh) 2001-02-21
KR100755154B1 (ko) 2007-09-04
TR200001981T2 (tr) 2000-11-21
ATE312602T1 (de) 2005-12-15
PL193776B1 (pl) 2007-03-30
SK284988B6 (sk) 2006-04-06
CN1171582C (zh) 2004-10-20
MA26576A1 (fr) 2004-12-20
TNSN98229A1 (fr) 2005-03-15
EP1043976B1 (en) 2005-12-14
DZ2685A1 (fr) 2003-03-29
SK8072000A3 (en) 2001-01-18
HK1034455A1 (en) 2001-10-26
JP4865945B2 (ja) 2012-02-01
US6605303B1 (en) 2003-08-12
EE04901B1 (et) 2007-10-15
JP2001526211A (ja) 2001-12-18
CZ299228B6 (cs) 2008-05-21
BR9814378A (pt) 2000-10-10
BG104620A (en) 2001-04-30
MY126555A (en) 2006-10-31
ZA9811239B (en) 1999-06-22
AU1991299A (en) 1999-07-12
HUP0101437A3 (en) 2003-01-28
ES2252875T3 (es) 2006-05-16
PL341428A1 (en) 2001-04-09
AU759634B2 (en) 2003-04-17
NZ505127A (en) 2003-02-28
TWI249410B (en) 2006-02-21
WO1999032091A1 (en) 1999-07-01
SE9704869D0 (sv) 1997-12-22
CA2315261C (en) 2008-02-12
BG65028B1 (bg) 2006-12-29
DE69832816D1 (de) 2006-01-19
IL136827A0 (en) 2001-06-14
NO20003218L (no) 2000-08-22
KR20010033428A (ko) 2001-04-25
DK1043976T3 (da) 2006-03-20
NO20003218D0 (no) 2000-06-21
RU2214232C2 (ru) 2003-10-20
CA2315261A1 (en) 1999-07-01
SA99191077B1 (ar) 2006-07-11

Similar Documents

Publication Publication Date Title
HRP20000380B1 (en) Oral pharmaceutical extended release dosage form
RS49590B (sr) Upotreba inhibitora h+,k+-atpaze za proizvodnju novih farmaceutskih preparata
TR200002681T2 (tr) 2-(2,6-Dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
HUP0300268A2 (hu) Herbicid hatású benzoilpirazolszármazékok, ilyeneket tartalmazó készítmények és alkalmazásuk
PE20010992A1 (es) Formulacion de liberacion sostenida de un inhibidor de ciclooxigenasa-2
PT795025E (pt) Preparacao enantiosselectiva de sulfoxidos farmaceuticamente aceitaveis por bio-reducao
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
HUP0201659A2 (hu) Kristályos benzimidazol-vegyület
MXPA02005604A (es) Aminobenzofenonas como inhibidores de il-1beta y tnf-alfa.
DK0869947T3 (da) Barbitursyrederivater, fremgangsmåder til fremstilling deraf og farmaceutiske midler, der indeholder disse forbindelser
ATE72436T1 (de) 2-(methyl(4-piperidinyl)>-1,2,3,4-tetrahydro-9h pyrido(3,4-b>indolderivate, ihre herstellung und therapeutische verwendung.
DK0941221T3 (da) Substituerede dihydrobenzofuraner som PDE-inhibitorer
HK1048464B (zh) 作為IL-1β和TNF-α的抑制劑的氨基二苯酮
DE60213087D1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
ATE234818T1 (de) Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE167855T1 (de) Propensäure derivate verwendbar als fungizide
ATE257833T1 (de) 2-arylalkylthio -imidazole, 2-arylalkenyl -thio - imidazole und 2-arylalkinyl -thio -imidazole als entzündungs -hemmstoffe und hemmstoffe der cytokin -freisetzung
IL132575A0 (en) Benzimidazole derivative
ATE191465T1 (de) Carbamoylcarbonsäureamide
DE69227461D1 (de) Anthelmintische benzimidazole
DE69425823T2 (de) Substituierte chinolinderivate, und ihre verwendung als inhibitoren der magensekretion
DK1023287T3 (da) Derivater af 3-oxo-(2H)-1,2,4-triazin som ligander for 5HT1a-receptorer

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071024

Year of fee payment: 10

PBON Lapse due to non-payment of renewal fee

Effective date: 20081218